Manara - Qatar Research Repository
Browse
10.1002_ccr3.5467.pdf (142.22 kB)

Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature

Download (142.22 kB)
journal contribution
submitted on 2023-03-15, 08:02 and posted on 2023-03-16, 06:21 authored by Ahmad Al Bishawi, Hamad Abdel Hadi, Eman Elmekaty, Musaed Al Samawi, Arun Nair, Mohammed Abou Kamar, Muna Al Maslamani, Alaaeldin Abdelmajid

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.

Other Information

Published in: Clinical Case Reports
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: http://dx.doi.org/10.1002/ccr3.5467

History

Language

  • English

Publisher

Wiley

Publication Year

  • 2022

Institution affiliated with

  • Hamad Medical Corporation

Usage metrics

    Manara - Qatar Research Repository

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC